ESR1 and type 2 diabetes mellitus: Following subsequent network pharmacological analyses, pivotal targets of GQD for the concurrent treatment of T2DM and UC were identified, including AKT1, BCL2, EGFR, ESR1, PTGS2, STAT3, and TNF.